Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Cyclacel begins phase II sapacitabine trial in previously treated NSCLC patients

Jan. 15, 2009

ASA-404 enters pivotal phase III second-line lung cancer trial

Jan. 15, 2009

Genta updates progress of phase III trial of Genasense in advanced melanoma

Jan. 15, 2009

EpiCept to focus on Ceplene and discontinue drug discovery operations

Jan. 15, 2009

Array BioPharma initiates phase I clinical trial for MEK inhibitor ARRY-300

Jan. 14, 2009

UCB and Wilex sign strategic alliance to develop UCB's preclinical oncology portfolio

Jan. 14, 2009

Poniard presents 2009 clinical goals for development of chemotherapy drug picoplatin

Jan. 13, 2009

CTI receives USD 7.5 million from Spectrum under U.S. joint venture agreement for Zevalin

Jan. 13, 2009

Aegera initiates phase II AEG-35156 trial in non-small cell lung cancer

Jan. 12, 2009

Fasgen and Centocor sign research and license agreement in oncology

Jan. 12, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...